Anthony J. Guarascio, PharmD, BCPS

• Assistant Professor, Department of Pharmacy, Practice, Mylan School of Pharmacy
• Duquesne University, Pittsburgh, Pennsylvania

https://www.duq.edu/assets/Documents/pharmacy/Faculty%20CVs/2017-18/Guarascio.pdf

Susceptibility of staphylococci and enterococci to antimicrobial agents at different ward levels in four north European countries medicine you can take while pregnant coversyl 4 mg lowest price. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock medicine you can take during pregnancy order coversyl 8 mg with mastercard. The impact of timing of antibiotics on outcomes in severe sepsis and septic shock: a systematic review and meta-analysis treatment 3rd degree av block buy coversyl toronto. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy symptoms of dehydration coversyl 8mg buy. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis medications of the same type are known as coversyl 4mg order mastercard. Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock. Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients. The effect of pathophysiology on pharmacokinetics in the critically ill patient ­ concepts appraised by the example of antimicrobial agents. Rapid detection of enterobacteriaceae producing extended spectrum beta-lactamases directly from positive blood cultures by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Rapid diagnosis of infection in the critically ill, a multicenter study of molecular detection in bloodstream infections, pneumonia, and sterile site infections. Integration rapid pathogen identification and antimicrobial stewardship significantly decreases hospital costs. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia; retrospective study of impact of combination antimicrobial therapy. Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. Ciprofloxacin use in critically ill patients: pharmacokinetic and pharmacodynamic approaches. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Optimal tigecycline dosage regimen is urgently needed: results from a pharmacokinetic/ pharmacodynamic analysis of tigecycline by Monte Carlo simulation. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Determinants of early inadequate vancomycin concentrations during continuous infusion in septic patients. Prolonged infusion versus intermittent boluses of -lactam antibiotics for treatment of acute infections: a meta-analysis. Extended versus bolus infusion of meropenem and piperacillin: a pharmacokinetic analysis. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Insufficient -lactam concentrations in the early phase of severe sepsis and septic shock. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. An international multicentre survey of -lactam antibiotic therapeutic drug monitoring practice in intensive care units. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting Intravenous colistin in a patient with serious burns and borderline syndrome: the benefits of therapeutic drug monitoring. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods The application of population pharmacokinetic modeling to individualized antibiotic therapy. Assays for therapeutic drug monitoring of -lactam antibiotics: a structured review. Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Nebulized antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis. Pletz3,4,5 the use of inhaled antibiotics against chronic Pseudomonas aeruginosa infection has been a success story which has significantly contributed to the steadily improving overall survival in patients with cystic fibrosis. Suppressive inhaled antibiotic therapy has been shown to be effective with regard to improvement of clinical symptoms and quality of life. It improves lung function and slows down deterioration of lung function in the long term, while it may also decrease exacerbation frequency and prolong the time to next exacerbation. In this article, we summarise the basic concepts, differential indications and future perspectives for the use of inhaled antibiotics in chronic airway infections. At that time, treatment success was limited by the lack of efficient inhalation devices and nebulisers as well as side-effects due to irritating preservatives. Ringshausen, Hannover Medical School, Dept of Respiratory Medicine, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. However, several aspects may limit the efficacy of pulmonary deposition of inhaled antibiotics, including bronchial obstruction with viscous mucus, bacterial biofilm formation and drug-related side-effects. In addition, inhomogeneous ventilation in structurally damaged airways penalises those areas of the lungs that are affected most and would likely benefit most from targeted antimicrobial treatment [6]. Although often consisting of established compounds without protection by patents, most of the available inhaled antibiotic agents are very costly. Thus, their long-term use puts significant economic pressure on healthcare systems. Moreover, in many countries the off-label prescription of inhaled antibiotics poses a significant financial risk for the prescribing physician. Therefore, as shown in table 1, inhaled antibiotics should always be accompanied by an optimised backbone treatment regimen, including identification and specific treatment of the underlying condition, smoking cessation, influenza, pertussis and pneumococcal vaccinations, pulmonary rehabilitation, and effective airway clearance techniques. Moreover, special attention should be paid to the inhalation device and/or nebuliser, inhalation technique, and hygiene measures in order to prevent recurrent infections from contaminated equipment. A suitable nebuliser should have a high aerosol output rate, including high density of nebulae and short inhalation time, a defined particle size and mass fraction <5 µm, a minimised aerosol loss to the environment, a low residual amount of the drug after nebulisation, and should be easy to clean. Hygiene measures should include cleaning after every use, disinfection in boiling water for 5 min or vaporisation at least once daily, drying for a minimum of 4 h and appropriate storage. A qualified chest physiotherapist should verify the correct inhalation technique and the implementation of hygiene measures at least once a year. Choice of inhalation device, inhaled antibiotic and mode of administration Some inhaled antibiotics are available as dry powder inhalations. In general, this mode of administration has the advantages of breath-triggered inhalation, easy handling, portability, short inhalation times and reduced risk of contamination. However, disadvantages include that inhalation is airflow dependent, thus limiting their use in very advanced stages of disease, and moreover, the potential agglutination of powders, the fact that often patients are uncertain about the efficacy of the inhalation manoeuvre and the limited line-up of available compounds. In contrast, there are a variety of different nebulisers and nebuliser systems available for use in different patient populations, such as jet nebulisers, ultrasound nebulisers, mesh nebulisers and intermittent positive-pressure breathing devices, each with advantages and disadvantages. They are efficient, robust, affordable and easy to clean, and can be used in parallel with airway clearance devices and techniques. However, they usually require 15­20 min per inhalation session and are stationary as well as quite noisy due to the characteristic compressor unit. In contrast, mesh nebulisers generate aerosols by forcing the agent-containing liquid through a membrane (mesh) with defined porosity. Typically, they offer the same efficacy in 4­5 min in a silent and portable fashion, and thus may facilitate patient adherence. Moreover, mesh nebulisers (including their spare parts) are cost-intensive devices. Generally, only nebulisers and inhalation devices that have been licensed for the use of each particular inhaled antibiotic should be used. However, different devices may be chosen on an individual basis for nebulisation or inhalation. In real life, issues with health insurance companies often prevent necessary prescriptions of inhaled antibiotics for patients with chronic P. In principle, inhaled antibiotics should be used according to their approval as 28-days on/off treatment cycles or continuously. However, since then, only limited data supporting this theory have emerged and the clinical relevance of the development of resistance with the use of inhaled antibiotics is still unclear [11]. If the clinical condition is critical or deteriorating despite an optimised multimodal backbone therapy, intensification of the inhaled antimicrobial treatment regimen should be considered and is commonly practised, i. While healthy and well-ventilated areas of the lung achieve very high concentrations of inhaled antibiotics, concentrations are considerably lower in diseased areas with poor ventilation [6]. When comparing different modes of inhaled antimicrobial drug delivery, dry powder inhalations apparently produce higher pulmonary drug concentrations than nebulised solutions. Neither the European Committee on Antimicrobial Susceptibility Testing nor the Clinical and Laboratory Standards Institute has established breakpoints for the in vitro resistance testing for inhaled antibiotics. However, the clinical benefit of implementing these breakpoints has not yet been established, as in a Spanish study lung function improved with tobramycin inhalation in all groups regardless of the applied definition of resistance [13]. Thus, given the lack of evidence for its clinical benefit, antimicrobial resistance testing should not be used to guide therapy with inhaled antibiotics against chronic P. Monitoring of side-effects and toxicity In general, serum levels of inhaled antibiotics are low and do not exhibit significant differences between inhalation techniques. Although they may show considerable individual variability, we do not consider regular monitoring of serum levels to be necessary. However, combined high-dose inhaled and parenteral aminoglycoside therapy should be avoided in order to reduce the risk of toxicity. Apart from those measures stated previously in the summary of medicinal product characteristics, symptom-orientated individual monitoring of side-effects and toxicity may be implemented. In particular, this monitoring may include audiometry and laboratory parameters for renal function. In addition, supervision of the first application of a newly introduced inhaled antibiotic should be considered, in order to provide training for the correct inhalation technique and to guarantee tolerance of the novel drug or formulation. A simple approach to rule out acute bronchoconstriction is to repeat spirometry (15 and) 30 min after the first supervised inhalation of the respective inhaled antibiotic, in particular if lung function is severely impaired or if the drug is used off-label. Use of a fast-acting bronchodilator prior to administration of inhaled antibiotics should be considered in order to optimise drug delivery and reduce the risk of bronchospasm. Management of side-effects If clinically relevant side-effects occur after the use of an inhaled antibiotic and a fast-acting bronchodilator has already been applied beforehand, the switch to another preparation or compound should be considered. Prior inhalation of a fast-acting bronchodilator may prevent bronchospasm and, therefore, is strongly recommended. Too fast and forceful inhalation manoeuvres lead to increased deposition of powder in the throat and thus may provoke cough.

Phenotypic modulation of smooth muscle cells during the formation of neointimal thickenings in the rat carotid artery after balloon injury: an electron-microscopic and stereological study symptoms 5 days after iui 4 mg coversyl order. Injury induces dedifferentiation of smooth muscle cells and increased matrixdegrading metalloproteinase activity in human saphenous vein adhd medications 6 year old coversyl 8 mg buy cheap. Production of platelet-derived growth factor-like molecules by cultured arterial smooth muscle cells accompanies proliferation after arterial injury medications management cheap coversyl 4 mg buy online. Rat aortic smooth muscle cells isolated from different layers and at different times after endothelial denudation show distinct biological features in vitro medicines360 purchase 8 mg coversyl with amex. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery medications 4 times a day cheap coversyl 8 mg with mastercard. Smooth muscle cells isolated from discrete compartments of the mature vascular media exhibit unique phenotypes and distinct growth capabilities. Heterogeneity of smooth muscle cell populations cultured from pig coronary artery. Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse. Arrangement of desmin intermediate filaments in smooth muscle cells as shown by high-resolution immunocytochemistry. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Intimal smooth muscle cells of porcine and human coronary artery express S100A4, a marker of the rhomboid phenotype in vitro. Smoothelin-B deficiency results in reduced arterial contractility, hypertension, and cardiac hypertrophy in mice. S100A4/ Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Cell-cell interactions mediate the response of vascular smooth muscle cells to substrate stiffness. The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Isolation of a morphologically and functionally distinct smooth muscle cell type from the intimal aspect of the normal rat aorta. Longitudinal gradients of collagen and elastin gene expression in the porcine aorta. Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster. The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. A necessary role of miR-221 and miR-222 in vascular smooth muscle cell proliferation and neointimal hyperplasia. Molecular basis of the effects of mechanical stretch on vascular smooth muscle cells. Cellular and molecular effects of mechanical stretch on vascular cells and cardiac myocytes. Biomechanical regulation of vascular smooth muscle cell functions: from in vitro to in vivo understanding. Effects of cyclic strain and growth factors on vascular smooth muscle cell responses. Physiological cyclic stretch causes cell cycle arrest in cultured vascular smooth muscle cells. Development of a smooth muscle-targeted cre recombinase mouse reveals novel insights regarding smooth muscle myosin heavy chain promoter regulation. Expression of human smooth muscle calponin in transgenic mice revealed with a bacterial artificial chromosome. Serum response factor is essential for mesoderm formation during mouse embryogenesis. The serum response factor coactivator myocardin is required for vascular smooth muscle development. Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells. Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Mechanical strain increases smooth muscle and decreases nonmuscle myosin expression in rat vascular smooth muscle cells. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. Vascular aging: insights from studies on cellular senescence, stem cell aging, and progeroid syndromes. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Progressive vascular smooth muscle cell defects in a mouse model of HutchinsonGilford progeria syndrome. Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase-deficient mice. During angiogenesis, new capillaries sprout from pre-existing vessels to expand an initial vascular plexus (1). The resulting increase in capillary density of the plexus enhances perfusion of the tissue and secures adequate oxygen and nutrient supply. Angiogenesis occurs only rarely after birth in healthy conditions, but is crucial for wound healing and tissue regeneration, and also permits tumours to acquire the large amounts of nutrients required for excessive growth (3). Although formerly considered a variant of angiogenesis, arteriogenesis covers two highly specific processes. In a developmental setting, arteriogenesis entails the formation of the arterial vessel network (versus the venous and capillary network) from the primitive vascular plexus (4). In adulthood, arteriogenesis more commonly describes the radial growth of arteries to increase bulk blood flow (5). It is then mainly considered to be a pathophysiological process in which, upon occlusion of a main feeding artery, pre-existing interconnecting collateral arterioles are remodelled into mature, large conductance arteries. The primary function of these collaterals is to serve as a natural bypass and to redirect and secure blood flow to peripheral tissues in need of nutrient supply. Remodelling of pre-existing vessels is a feature that distinguishes arteriogenesis from angiogenesis. Furthermore, unlike for angiogenesis, shear stress and not hypoxia is the main trigger for arteriogenesis (6, 7) (see % Modulation of vascular growth). Sprouting angiogenesis can be described as a series of continuous processes that are initiated by pro-angiogenic stimuli. The formation of the initial, primitive vascular plexus occurs through vasculogenesis. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Newly formed sprouts eventually meet and connect through a process called anastomosis, creating a closed tubular system. Although tip and stalk cells arise from pre-existing blood capillaries, they bear distinct morphology and functional properties. While tip cells display a highly motile phenotype with multiple filopodia and cell protrusions, stalk cells have few filopodia and adopt various cell shapes (13). Perivascular cell recruitment is the last step in creating a fully functional blood vessel. Intussusceptive growth permits remodelling of the plexus and can increase the density of a capillary bed by creating two adjacent vessels from one single capillary. In disease (cancer), other modes of vessel formation exist (17) (see % Therapeutic opportunities). Upon further development, a primitive plexus no longer suffices to efficiently perfuse the organs and remodelling of the plexus into an ordered network of capillaries, arteries, and veins is required (2). Most arteries feed into smaller size arterioles, which further branch into even smaller diameter capillaries (resembling a tree-branching pattern), with blood flowing from the proximal larger artery towards the distal extreme capillary. In these collaterals, blood does not flow along a proximal­distal axis but from the two opposite extremes towards the smaller branches on the collateral. The role of collateral arteries, which are the subject of pathological arteriogenesis in adult life, in embryonic development is less well understood (19). Postnatal angiogenesis and arteriogenesis During adult life, vessels are quiescent but retain the remarkable ability to sprout. Vessel growth during tissue regeneration, as occurs in wound healing or in the cyclical changes in female reproductive organs, are examples of non-developmental angiogenesis. However, active postnatal angiogenesis is mostly linked to uncontrollable vessel growth and deviant microvascular networks in pathological settings, such as diabetic retinopathy, inflammation, and tumourigenesis. Composed of morphologically aberrant, tortuous, and leaky vessels, which often lack normal venous versus arterial specification and normal blood flow dynamics, the excessive but inadequately perfused tumour microvasculature fails its primary function, namely the supply of oxygen and nutrients to the growing tumour. The hypoperfusion combined with the continuously increasing metabolic demand of the growing tumour mass not only fuel a nonstop cascade of aberrant non-productive angiogenesis, but also render the tumour microenvironment increasingly harsh. Interstitial pressure and acidity increase in the tumour microenvironment and allow only resistant cancer cells to survive, but promotes others to escape the hostile microenvironment, thereby favouring metastasis (17, 20). Importantly, the structurally and functionally abnormal vasculature and the increased tumour interstitial pressure also impede efficient delivery of chemotherapeutics to the tumour (21) (see % Therapeutic opportunities). Arteriogenesis in the adult setting denotes the formation of arteries upon obstruction of an adjacent arterial trunk in vascular occlusive diseases. Blood flow is redirected to pre-existing collateral anastomoses where altered fluid shear stress initiates the remodelling processes leading to increased lumen diameter and increase in number of smooth muscle layers. The massive (up to 50-fold) increase in diameter and concomitant thickening of the arterial wall upon acute arterial occlusion is unique for the collateral circulation and occurs during four distinct phases (for a review see (% 19)). Due to these abnormalities, tumour vessels fail to deliver oxygen and increase hypoxia in tumour tissue. Monocytes produce fibronectin, proteoglycans, and proteases to remodel the extracellular matrix, which allows remodelling processes to increase radial growth of the vessel wall. Vascular dysfunction due to vessel occlusion or rupture can lead to decreased O2 delivery and is a pathogenic driver in peripheral artery disease and ischaemic heart disease. Hypoxia emerges when changes in the O2 supply or demand occur and is a common feature in both normal mammalian development and human disease. In regions of tissue ischaemia, angiogenesis and arteriolar growth have been observed. Tissue hypoxia drives the development of new blood vessels from existing blood vessels (angiogenesis), and the remodelling of existing collateral vessels (arteriogenesis), in order to secure sufficient tissue perfusion and oxygenation. Angiogenesis or capillary sprouting towards the ischaemic tissue remedies the local hypoxia, whereas arteriogenesis restores the bulk blood supply and bypasses the vascular occlusion. Pharmacological activation of Trpv4 increased cerebral arteriogenesis and collateral flow (39); conversely, a Trpv channel-blocker tended to reduce collateral flow (37). The role of monocytes/macrophages in these processes is discussed in the following section. Induction of expression of these genes also facilitates adaptation to hypoxia, due to improved oxygen delivery as a result of more active angiogenesis. Shear stress as a modelling force in arteriogenesis Similar to angiogenesis, where new capillaries sprout from pre-existing ones, arteriogenesis also relies on the presence of pre-existing arterioles. In the adult, arteriogenesis occurs as a consequence of vessel occlusion, which leads to the remodelling and growth of collateral arterioles from preexisting anastomoses. Angiogenesis is ischaemia-driven but for the initiation of arteriogenesis, hypoxia does not seem to be the driving mechanism (29). The available evidence sustains the hypothesis that mechanical forces caused by the altered blood flow dynamics upon arterial occlusion lead to the induction of collateral remodelling. In particular, monocyte migration and infiltration to the perivascular area of growing collaterals is associated with improved arteriogenesis. Pharmacological depletion of monocytes results in impaired arteriogenesis in rabbit and mouse models of hindlimb ischaemia (43, 45, 46). The expression and composition of vessel- and tissue-derived cytokines is tightly regulated at the ischaemic site, and affects the angiogenic and arteriogenic function of macrophages. Of note, in addition to monocytes/macrophages, other immune cell types like T-lymphocytes play crucial roles in angiogenesis and arteriogenesis; these are not discussed here but more details can be found in the following references (56, 57). Macrophages are recruited to ischaemic sites where they (in response to tissuederived factors) switch their phenotype to potent angiogenic and arteriogenic (M2- like) cells. The patterning of artery and vein identity is essential for normal embryonic development and the subsequent function of the circulatory system. The loss of a single allele of Vegfa is sufficient to induce early embryonic (embryonic day (E) 8. For the most recent insights in molecular mechanisms of angiogenesis/arteriogenesis in other model systems. Simplified scheme of signalling cascades involved in arterial versus venous specifications. Different splice variants of the Vegfa gene (Vegf120, Vegf164, and Vegf188) have distinct effects on vascular development. Recent work has established that genetic pre-patterning mediated by Notch signalling also plays a primary role in regulating arteriovenous differentiation. For instance, expression of the Notch ligand Dll4 is initially restricted to large arteries in the embryo, whereas in adult mice and tumour models, Dll4 is specifically expressed in smaller arteries and microvessels. The Fox transcription factors, Foxc1 and Foxc2, can act as regulators of arterial cell specification by directly activating the Dll4 promoter. Much like those lacking Dll4, mice deficient in the Notch1 and -4 receptors also display severe vascular remodelling defects (73).

Clarithromycin is metabolised by the liver and has a relatively long half-life xanax medications for anxiety coversyl 4mg cheap, allowing twice-daily administration symptoms 5-6 weeks pregnant order cheap coversyl. Tetracyclines: doxycycline Doxycycline shows a bioavailability of >80% with higher absorption and lipid solubility compared with earlier drugs medicine for runny nose purchase 8mg coversyl with visa. Peak concentrations are achieved in 2­3 h and the elimination half-life ranges from 12 to 25 h symptoms 7dp3dt generic coversyl 4 mg without prescription. In patients with chronic renal failure medicine 48 12 buy coversyl once a day, the serum half-life of doxycycline is not greatly increased, peak plasma concentration (Cmax) is unchanged and dose modification is usually not needed [41]. In the late 1990s, newer molecules, the "respiratory fluoroquinolones", including levofloxacin, gatifloxacin, gemifloxacin and moxifloxacin, became available for the treatment of pneumonia [44]. The characteristics of these compounds included a broad spectrum of activity, excellent bioavailability and long half-lives, allowing once-daily administration. Furthermore, drug­drug interactions are usually minor, although all new fluoroquinolones react with metal ions and should be administered at least 2 h apart from antacids [45]. After oral administration, levofloxacin is absorbed rapidly, reaching its Cmax in 2 h [53, 54], and is widely distributed in the lungs, epithelial lining fluid and alveolar macrophages [55, 56]. Levofloxacin is eliminated mainly through the kidneys, with a mean elimination half-life of 8 h, but significant increases were shown for a creatinine clearance of <50 mL·min-1, requiring dosage adjustment to avoid drug accumulation [53, 54]. Noninferiority of short (750 mg once daily for 5 days) versus long (500 mg once daily for 10 days) courses of i. Levofloxacin administered in 750 or 500 mg regimens is generally well tolerated [56, 57]. The most common adverse effects include nausea, vomiting, diarrhoea, abdominal pain, headache, photosensitivity reactions and Clostridium difficile infection [58]. An increased risk of severe tendon disorders in the elderly is also reported [59, 60]. Moxifloxacin is characterised by enhanced staphylococcal activity and reduced propensity to resistance and phototoxicity due to the presence of a C-8 methoxy group [61]. Moxifloxacin has potent bactericidal activity against intracellular and extracellular respiratory pathogens, including -lactamase-producing H. The terminal elimination half-life is 12 h, supporting once-daily dosing [65, 66]. Similar to levofloxacin, moxifloxacin has low protein affinity (48%) and is characterised by high penetration in respiratory tract tissues [65, 66]. Although moxifloxacin is excreted by the hepatic and renal routes, renal impairment does not significantly affect its oral clearance [67]. Moxifloxacin appeared to be well tolerated in a study collecting adverse effects from clinical trials and post-marketing studies from over 50 000 patients. Various studies, however, have highlighted a correlation between fluoroquinolone use and C. Antimicrobial resistance can cause delays in the onset of an adequate therapy and is associated with increased mortality, length of hospital stay and healthcare costs [80]. Recommended empirical therapy for pulmonary infections in adults according to the setting and severity of presentation [73, 74]. Studies have reported concentrations of 41% in lung tissue and 52% in the epithelial lining fluid [82, 88]. In critically ill patients, penetration of vancomycin into the epithelial lining fluid ranged from 0 to 8. Other adverse effects associated with vancomycin use include aminotransferase elevations, neutropenia and infusion reactions [94, 95]. Oxazolidinones: linezolid Linezolid binds to the bacterial ribosome 50S subunit and interferes with protein synthesis [96]. Linezolid plasma protein binding is low (31%), while its volume of distribution approximates to the total body water content (40­50 L). Although no drug adjustments are necessary for patients with renal impairment or mild to moderate liver disease [100], it is recommended that linezolid is used with caution in patients with severe renal insufficiency. Initial studies confirmed excellent concentrations of linezolid in the epithelial lining fluid [101]. Use of linezolid, however, has been associated with the onset of various adverse effects including nausea, headache, peripheral and optic neuropathy, lactic acidosis and myelosuppression (especially thrombocytopenia). The majority of the effects were reported during prolonged regimens (>14 days) and in patients with renal impairment [103, 104]. Linezolid is also a reversible monoamine oxidase inhibitor and can interact with selective serotonin reuptake inhibitors [105]. Limitations in the use of colistin, however, include unclear pharmacokinetic/pharmacodynamic parameters and dosing regimen, poor lung penetration and renal toxicity [109]. Other antimicrobials used in the treatment of pneumonia include aztreonam, characterised by excellent tolerability but limited by a narrow antimicrobial spectrum including only Gram-negative bacteria, and aminoglycosides. Although the efficacy of many new compounds still needs to be confirmed, promising features include a broad spectrum of activity, limited risk of antimicrobial resistance, availability of i. Table 2 summarises the characteristics and current approval status of new antimicrobials that have been studied for the treatment of pulmonary infections. Due to its good penetration into lung tissue, ceftazidime­avibactam represents a good option for the treatment of pulmonary infections caused by carbapenem-resistant Gram-negative bacteria [121, 122]. Ceftolozane­tazobactam is the association of a new antipseudomonal cephalosporin with tazobactam, a well-known -lactamase inhibitor. Ceftolozane possesses a potent antipseudomonal activity and is not affected by mechanisms of resistance that are typical of P. Ceftolozane­tazobactam is currently approved for the treatment of complicated intra-abdominal and complicated urinary tract infections. Although ceftolozane­ tazobactam has shown good epithelial lining fluid penetration, pharmacokinetic/ pharmacodynamic studies have suggested that an increased dosage might be necessary for the treatment of pneumonia in order to achieve an optimal response [126, 127]. Fluoroketolides Solithromycin is a fourth-generation macrolide antibiotic and the first fluoroketolide within the macrolide class. Multiple interacting sites are involved in its low resistance rates and improved activity against macrolide-resistant isolates of S. Solithromycin has activity against the most common respiratory pathogens and atypical bacterial pathogens, including Legionella pneumophila, shows bactericidal activity against most isolates of S. When administered as 400 mg once daily, solithromycin had a bioavailability of 67% and a plasma half-life of 10 h [128]. Solithromycin is excreted primarily by the liver and no dose adjustment is needed in patients with hepatic impairment. The drug­drug interaction profile of solithromycin is consistent with that of previously approved macrolides [128]. Although a higher incidence of infusion site reactions was demonstrated in the solithromycin arm compared with moxifloxacin, other adverse effects were similar in the two arms. Telavancin acts by disrupting the bacterial membrane function and inhibiting bacterial wall synthesis via transglycosylation and transpeptidation, using a unique dual mechanism of action [133]. Oxazolidinones Among oxazolidinones, tedizolid is currently approved for the treatment of acute bacterial skin and soft tissue infections. Recent pharmacokinetic/pharmacodynamic studies confirmed high epithelial lining fluid concentrations of tedizolid in healthy volunteers after 200 mg of tedizolid administered orally, supporting its potential role in the treatment of pneumonia [141]. Fluorocyclines Eravacycline is a novel fluorocycline that is not influenced by the mechanisms that usually confer resistance to tetracyclines, such as efflux pumps and ribosomal protection proteins [144]. These data, together with the availability of an oral formulation, make eravacycline an attractive option for the treatment of respiratory infections. Characteristics of antimicrobials that are currently commonly used in the treatment of respiratory infections Class Spectrum Lung penetration Sequential therapy. Challenges in the treatment of respiratory infections encountered in clinical practice are the frequent absence of microbial diagnosis to guide antimicrobial choice and, in some areas, an increased rate of antimicrobial resistance among pathogens that are usually involved in these infections, especially in the nosocomial setting. A short course of antimicrobials should be favoured, where possible, to reduce resistance selection; de-escalation therapy should also be pursued to reduce length of hospital stay and healthcare costs. Limitations in the use of antimicrobials, however, include variable penetration in the lung tissue, availability only as an i. To overcome these issues and to face the emerging increase in resistance to antimicrobials, new molecules have been developed. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. Executive summary: management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. The etiology of community acquired pneumonia in Australia: why penicillin plus doxycyline or a macrolide is the most appropriate therapy. Empiric piperacillin­tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum -lactamase-producing Enterobacteriaceae. Bactericidal activity, post antibiotic effect and modified controlled effective regrowth time of meropenem at high concentrations. Continuous versus intermittent intravenous administration of antibacterials with time-dependent action: a systemic review of pharmacokinetic and pharmacodynamic parameters. Comparison of the clinical and bacteriological efficacy of clarithromycin and erythromycin in the treatment of streptococcal pharyngitis. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. Simplified treatment of acute lower respiratory tract infection with azithromycin: a comparison with erythromycin and amoxicillin. Clarithromycin in the treatment of community-acquired lower respiratory tract infections. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. Fluoroquinolone resistance: overuse of fluoroquinolones in human and veterinary medicine can breed resistance. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antacid interaction with new quinolones: dose regimen recommendations based on pharmacokinetic modeling of clinical data for ciprofloxacin, gatifloxacin and norfloxacin and metal cations. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. The Alexander Project 1998­2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and Monte Carlo simulation. Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study. Structure­activity and structure­side-effect relationships for the quinolone antibacterials. A review of new fluoroquinolones: focus on their use in respiratory tract infections. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Epidemiology and predictors of multidrug-resistant community-acquired and healthcare-associated pneumonia. The impact of multidrug resistance on the outcomes of critically ill patients with Gram-negative bacterial pneumonia. Epidemiology of methicillin-resistant Staphylococcus aureus pneumonia in community hospitals. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Vancomycin pharmacokinetics, renal handling, and nonrenal clearances in normal human subjects. Plasma and intrapulmonary concentrations of oritavancin and vancomycin in normal healthy adults. In: Program and Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, May 1­4, 2004. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

This enzyme is present in lysosomes throughout the body medications derived from plants safe coversyl 4mg, and thus the disease manifestations are systemic symptoms 8 dpo bfp buy coversyl 4 mg free shipping. Heterozygous females may also be affected medications 222 coversyl 8mg lowest price, although typically with milder manifestations symptoms 7 weeks pregnancy purchase generic coversyl line. Renal disease has been postulated to be related to podocyte injury consequent to the marked accumulation of Gb3 in these cells medications bad for liver order discount coversyl line. In other studies, decreased peritubular capillary inclusions correlated with improvement after replacement enzyme therapy. Differential Diagnosis of Fabry Disease · Hydrochloroquine or other drugs that inhibit lysosomes may result in similar inclusions. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. Most described patients have been Japanese or Chinese, but the disease has also been rarely described in patients of other ethnicities. Patients typically have increased beta-lipoprotein and pre-beta-lipoprotein with elevated serum levels of apolipoprotein E (Apo E). Approximately one-third of patients show slowly progressive renal disease, and the lesions may recur in renal transplants. In areas that do not show mesangiolysis, there is increased mesangial cellularity and matrix. By immunofluorescence, there may be IgM, C1q, and fibrinogen surrounding the lipoprotein thrombi, which contain beta-lipoprotein, Apo B, and Apo E. There are massive intraluminal pale lipid thrombi in the glomerular capillaries, distending the capillary lumens, with segmental glomerular basement membrane splitting (Jones silver stain, ×200). Barry stokes, New york-presbyterian hospital at the Columbia university medical Center). The intracapillary thrombi stain brightly positive for lipid (oil red o stain, ×200). The intracapillary thrombi have a concentric, laminated pattern with small lipid vacuoles (transmission electron microscopy, ×8000). A rare case of lipoprotein glomerulopathy in a white man: an emerging entity in Asia, rare in the white population. Histiocytic and nonhistiocytic glomerular lesions: Foam cells and their mimickers. Lipoprotein glomerulopathy: Glomerular lipoprotein thrombi in a patient with hyperlipoproteinemia. A case of nephrotic syndrome with glomerular lipoprotein deposition with capillary ballooning and mesangiolysis. The disease was originally described in Scandinavian patients, but occurs worldwide, and is inherited as an autosomal recessive trait with varying plasma levels of lecithin-cholesterol acyltransferase in different kindreds. Patients have proteinuria, anemia, hyperlipidemia, corneal opacities (so-called "fish eye disease"), and accelerated atherosclerosis. Early kidney disease manifests as proteinuria even in childhood, increasing in severity by the fourth and fifth decades, frequently progressing to nephrotic syndrome and end-stage renal disease. The mesangium is expanded, and there is variable foam cell infiltrate within capillary lumens and in mesangial areas, as seen on the left (Jones silver stain, ×100). The focal prominent endocapillary foam cell infiltration is evident, with only minimal foam cells in the glomerulus on the right (periodic acid­schiff, ×200). The different mutations result in varying enzyme levels, ranging from absolute absence in some kindreds, to 10­20% of normal levels in some homozygotes. Lipid accumulations have been documented in aorta, other arteries, liver, spleen, and cornea. The glomerular basement membrane is thickened, with occasional double contours (bottom left). There are prominent intracapillary foam cells, with rare lipid vacuoles, and increased mesangial matrix (Jones silver stain, ×400). Numerous lipid inclusions are seen within the intracapillary foam cells by electron microscopy (transmission electron microscopy, ×8000). Recently, knockout mice have been generated, creating a method for testing new gene therapy approaches. Deposition of these lipid-related materials with foam cells in glomeruli recurs as early as 6 months after transplantation although renal function is usually maintained. Familial lecithin:cholesterol acyltransferase deficiency: a new metabolic disease with renal involvement. Renal lesions in familial lecithin-cholesterol acyltransferase deficiency: ultrastructural heterogeneity of glomerular changes. An aid to the diagnosis of genetic disorders underlying adult-onset renal failure: a literature review. Lecithin cholesterol acyltransferase deficiency: ultrastructural examination of sequential renal biopsies. Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase-deficient mice. Although there are no reliable morphologic clues as to the genetic nature of these diseases, an overview of the genetic mechanisms is provided. Unusual cytoplasmic electron-dense aggregates in podocytes, perhaps representing accumulated abnormal fragments of -actinin-4, have been observed. Importantly, patients with podocin mutations are generally resistant to steroid therapy. In families with steroid-resistant nephrotic syndrome, a causative mutation could be identified by elegant genetic testing with next-generation sequencing in about 30%. The disease is autosomal dominant, with the mutation causing enhanced cell surface expression of the channel. Several developed diabetes or hearing loss after onset of proteinuria in adolescence, with biopsy showing multinucleated podocytes and dysmorphic mitochondria. Patients had variable, occasional nephroticrange proteinuria but not full-blown nephrotic syndrome, adult onset, and frequently progressed to end-stage renal disease. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Specific podocin mutations determine age of onset of nephrotic syndrome all the way into adult life. The nature of the lesion on renal biopsy gives direct information relating to the severity of the autoimmune response within the kidney and aids in the selection of appropriate therapies and the prediction of both short- and long-term outcomes in individual patients. Analysis in this way not only gives a basis to correlate with clinical outcome but also offers a rationale for therapeutic manipulation. Classification of the biopsy findings in lupus is one of the few classifications of renal glomerular disease that is closely linked to therapeutic interventions, thus emphasizing its importance as a clinical tool. It combines all morphologic modalities of biopsy interpretation, including immunofluorescence and light and electron microscopic findings, and it thus represents a major improvement over previous versions of the classification. Modifications of this classification system, along with an assessment of severity and chronicity, are now in general use and have been accepted by clinical nephrologists and renal pathologists alike. It eliminates a class for biopsies with no significant findings and emphasizes the role of light microscopy and immunofluorescence without requiring electron microscopy since not all centers have access to the technology. All these classifications do have the limitation of focusing on the glomerular lesions without taking into consideration the significance of tubular, interstitial, and vascular lesions. Capillary thrombi are often seen in association with necrosis and indicate a possible contribution of anti-phospholipid antibodies in the pathogenesis. An ongoing review and reassessment of these and other issues of lupus classification will address these and other challenges. Other studies have shown that the new classification provides beneficial pathologic information relevant to the long-term renal outcome and the optimal therapy preventing end-stage renal disease and/or death. It does, however, provide a standardized approach to renal biopsy interpretation needed to compare outcome data across centers and studies. A recent review of the 2004 Classification has made some suggestions for improvements to assist in the next revision. The suggestions attempt to redefine and clarify interpretations of the morphologic findings and also to bring attention to the importance of other types of glomerular lesions as well as vascular and tubulointerstitial lesions. There is only minimal mild segmental mesangial widening without increased cellularity. In some cases, deposits occasionally are seen in the paramesangial subendothelial areas, or scattered subepithelial deposits are present. The mesangium contains an increase in mesangial matrix and small mesangial electron-dense deposits (transmission electron microscopy, ×4000). There is more prominent mesangial widening than in class i and there is a definite increase in mesangial cellularity. The adjacent tubules in interstitium are often uninvolved (hematoxylin and eosin, ×400). The immunoglobulins deposited in lupus almost always include igG, but a full house of immunoglobulin deposition involving multiple immunoglobulins and both classic and alternative pathway complement is characteristic of lupus nephritis (anti-igG immunofluorescence, ×400). The electron-dense deposits correspond to the deposition of immunoglobulins and complement seen by immunofluorescence (transmission electron microscopy, ×5000). Less than 50% of the glomeruli are involved with either active or chronic lesions. Endocapillary and extracapillary (ie, crescent) cell proliferations with obliteration of the capillary lumina are often found in addition to generalized mesangial widening. Necrotic lesions may be either segmental or rarely global and are usually associated with crescent formations that progress to segmental scars with focal capsular adhesions. The mesangial and peripheral capillary deposition of immunoglobulins appears more prominent than in class ii (anti-igG immunofluorescence, ×400). Some segments of peripheral capillary loops can be dramatically thickened because of plaque-like massive subendothelial deposits to form the so-called wire-loop lesion. Occasionally extensive deposits of immune complexes bulge into the capillary lumen, the so-called hyaline thrombi (which although smooth and glassy, ie, "hyaline" in appearance, are not true thrombi and do not contain fibrin). Segmental areas of sclerosis with broad-based adhesions are an indicator either of sequelae of previous segmental necrosis and/or crescents. The variety of lesions that can be encountered in this class ranges from diffuse mesangial hypercellularity without necrosis to a severe necrotizing and crescentic glomerulonephritis. About one-quarter of cases exhibit lobular accentuation because of endocapillary hypercellularity with mesangial extension and cellular interposition around the peripheral loops, forming a pattern similar to that of other forms of membranoproliferative glomerulonephritis. Multiple immunoglobulins frequently are encountered and generally are accompanied by evidence of the activation of inflammatory mediators, such as a deposition of both classic and alternative complement components, fibrinogen, and properdin. This pattern has been termed a full-house pattern of immunoglobulin and complement deposition. These deposits generally are larger and more abundant than in other classes of lupus nephritis. Mesangial hypercellularity with circumferential cellular interposition is associated with the light microscopic pattern of a membranoproliferative glomerulonephritis. This organized appearance most frequently is seen in the presence of abundant subendothelial deposits, but it can be present in all classes of lupus nephritis. The crystalline structure is thought by some to represent the presence of cryoglobulins, because similar structures are seen in patients with idiopathic mixed cryoglobulinemia. There are also numerous mesangial deposits (transmission electron microscopy, ×1500). Endothelial cell swelling and proliferation are prominent, and occasional mitotic figures of glomerular cellular components suggest active proliferation and regeneration secondary to activation of inflammatory cytokines and growth factors. The significance of these structures is unclear although their presence appears to correlate with disease activity. A major consequence of severe glomerular inflammation with necrosis is the development of both glomerular fibrous crescents and sclerosis, which results in decreasing glomerular filtration surface and contributes to progressive renal scarring and loss of function. The significance of these structures is still unclear, but they are associated with high levels of the cytokine alpha-interferon (transmission electron microscopy, ×15,000). The spikes are outward projections of membrane-like material between domes that correspond to the subepithelial and intramembranous deposits that are seen on immunofluorescence and electron microscopy. There is diffuse thickening of the peripheral, capillary walls associated with an increase in mesangial matrix. Where the wall of the capillaries is cut tangentially, there is a moth-eaten appearance of the capillary wall due to the deposits not staining with silver (Jones, ×400). The pattern is essentially identical to that seen in idiopathic membranous nephropathy, except that mesangial deposits usually are present, along with tubuloreticular inclusions. Often it cannot be distinguished from chronic sclerosing lesions from other etiologies. There is diffuse effacement of foot processes in a patient with lupus and nephrotic syndrome. The prompt response of some such patients to corticosteroids with remission of proteinuria supports possible minimal change disease­like injury. A typical clinical presentation is heavy proteinuria and renal insufficiency frequently with progression to end stage in the absence of a therapy-induced remission of proteinuria. This collapsing lesion is typically focal, and is seen with additional underlying focal or diffuse lupus nephritis with typical immune complexes. So-called pauci-immune necrotizing and crescentic glomerulonephritis differs from classical lupus nephritis in that glomerular necrosis and crescent formation are present in the absence of significant glomerular immune complex deposits. There is collapse of the glomerular architecture with mesangial sclerosis associated with hyperplasia of the visceral epithelium (hematoxylin and eosin, ×400). In both instances, treatment options may include plasmapheresis in addition to immunosuppressive therapy.

Coversyl 4 mg order online. What is Migraine Headache? - The Causes and symptoms of migraine headaches.

References

• Gosse P, Herpin D, Roudaut R, Malergue MC, Longy M, Baudet E, Dallocchio M. Myxoma of the mitral valve diagnosed by echocardiography. Am Heart J 1986;111:803-805.
• Wolfaardt J, Wilkes G, Parel S, et al. Craniofacial osseointegration: the Canadian experience. Int J Oral Maxillofac Implants 1993;8:197-204.
• Rini BI, Campbell SC, Escudier B: Renal cell carcinoma, Lancet (London, England) 373(9669):1119n1132, 2009. Rini BI, Garcia J, Elson P, et al: The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery, J Urol 187(5):1548n1554, 2012.
• Sonis ST. Oral mucositis. Anticancer Drugs 2011;22(7):607-12.